101 related articles for article (PubMed ID: 23452118)
1. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
[TBL] [Abstract][Full Text] [Related]
2. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
[TBL] [Abstract][Full Text] [Related]
3. Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
Wu QY; Ma MM; Zhang S; Cao J; Yan ZL; Chen C; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Sep; 136():209-219. PubMed ID: 31199972
[TBL] [Abstract][Full Text] [Related]
4. Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Wu QY; Ma MM; Zhang S; Liu Y; Cao J; Yan ZL; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Mar; 124():1123-1131. PubMed ID: 30521925
[TBL] [Abstract][Full Text] [Related]
5. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
Chen C; Li F; Ma MM; Zhang S; Liu Y; Yan ZL; Chen W; Cao J; Zeng LY; Wang XY; Xu KL; Wu QY
Int J Biol Macromol; 2019 Sep; 137():1030-1040. PubMed ID: 31299252
[TBL] [Abstract][Full Text] [Related]
6. Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells.
Wu QY; Ma MM; Tong YX; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2018 Oct; 117():271-279. PubMed ID: 29842959
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
9. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
10. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
[TBL] [Abstract][Full Text] [Related]
11. Effects of the I682F mutation on JAK2's activity, structure and stability.
Li F; Li W; Liu Y; Tong YX; Zhou P; Wang L; Chen C; Zeng LY; Wu QY; Wang XY; Xu KL
Int J Biol Macromol; 2015 Aug; 79():118-25. PubMed ID: 25940527
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M
Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039
[TBL] [Abstract][Full Text] [Related]
13. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
14. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
Malinge S; Ben-Abdelali R; Settegrana C; Radford-Weiss I; Debre M; Beldjord K; Macintyre EA; Villeval JL; Vainchenker W; Berger R; Bernard OA; Delabesse E; Penard-Lacronique V
Blood; 2007 Mar; 109(5):2202-4. PubMed ID: 17068151
[TBL] [Abstract][Full Text] [Related]
15. Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation.
Wu QY; Li F; Guo HY; Cao J; Chen C; Chen W; Zhao K; Zeng LY; Han ZX; Li ZY; Wang XY; Xu KL
Arch Biochem Biophys; 2012 Dec; 528(1):57-66. PubMed ID: 22960131
[TBL] [Abstract][Full Text] [Related]
16. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.
Roncero AM; López-Nieva P; Cobos-Fernández MA; Villa-Morales M; González-Sánchez L; López-Lorenzo JL; Llamas P; Ayuso C; Rodríguez-Pinilla SM; Arriba MC; Piris MA; Fernández-Navarro P; Fernández AF; Fraga MF; Santos J; Fernández-Piqueras J
Leukemia; 2016 Jan; 30(1):94-103. PubMed ID: 26216197
[TBL] [Abstract][Full Text] [Related]
17. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.
Wan S; Coveney PV
J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN
PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391
[TBL] [Abstract][Full Text] [Related]
19. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
20. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]